Gilead’s new HIV prevention drug lenacapavir will ‘change the face of HIV,’ says CEO ...
Gilead Sciences Inc (NASDAQ: GILD) is strongly positioned to “change the face of HIV” in 2025, according to its chairman and chief executive Daniel O’Day. He dubbed lenacapavir – the company’s twice-a ...
Fires, Hurricanes, Extreme Weather: The Media Misses the Climate Link
Protesting the fossil fuel industry and their political allies can help fix the narrative, and turn disasters into ...